Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care
Disease progression · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).
1 finding from 1 review
- RR 2.64 [1.29, 5.43]1 study · 129 participantsVery low